

From: Alfred Decker <pharma@smiconferences.co.uk>

To: Kester, Tonykester@aging.sc.gov

Date: 11/22/2016 4:17:23 AM

Subject: Targeting Drug Delivery with Big Pharma at RNA Therapeutics 2017 | Hear from Roche, GSK, AstraZeneca and Novartis

RNA Therapeutics 2017

8th annual conference: 22nd & 23rd February | Interactive workshop: 21st February
Cophthorne Tara Hotel, London, UK
Sponsored by Lipocalyx

£200 EARLYBIRD ENDS 30TH NOV

[Register](#) | [Brochure](#) | [NEW Interview](#)

Dear Mr Tony Kester,

Join SMI Group next February at the only event which draws from both scientific research and senior industry leaders driving medical progress. The exceptional speaker line-up includes **Roche, BioNTech, MHRA, Novartis, MiNA Therapeutics** and more. [Download a brochure](#) to take a look at the full line-up and detailed agenda for 2017.

EVENT UPDATE:

NEW Q&A: Read the [new interview](#) with Amotz Shemi, CEO of clinical stage biopharmaceutical company, Silenseed.

REGISTRATION UPDATE: £200 earlybird ends 20th Nov. Those who have recently confirmed include **Valneva, Diamond Biopharm, SilverRNA, University Of Twente** and **Cydan**.

Secure your place [here](#).

BIG PHARMA SPOTLIGHT:

SMi are thrilled to welcome expert insight through **SIX presentations** from **GSK, AstraZeneca, Novartis and Roche** in an exclusive big pharma spotlight at [RNA Therapeutics 2017](#).

Here is a snap shot of what to expect.

- 1. Self-Amplifying mRNA Vaccines! GSK Explain More**

The exclusive keynote presentation on mRNA vaccines from **Jeffrey Ulmer, Head of Preclinical Research & Development**, will delve further into areas such as immune response, animal models, platform technology and rapid response to emerging infectious diseases.

- 2. Unlock the Potential of Locked Nucleic Acids with Roche**

Respected for his extensive RNA experience and involvement in the Locked Nucleic Acid drug platform, **Dr Bo Rode Hansen Global Head of RNA Therapeutics Research**, will provide exciting new insights into RNA therapeutics drug discovery discussing significant updates

2. surrounding: drug candidates for diseases with difficult targets; next generation drugs; and new concepts on optimising the drug discovery process.
3. **Exploring Novel Paradigms for Therapeutic RNA Delivery with Novartis**
Nicole Meisner-Kober, Senior Investigator, RNA Biology, offers guidance into subcellular targeting to directly improve the therapeutic index and thus clinical viability of siRNA therapeutics. Recent data on how exosomes have evolved a specific route for cell entry will also be presented.
4. **AstraZeneca Talk Therapeutic Antisense Oligonucleotides in Oncology**
Senior Principal Scientist, Mark Edbrooke, presents on the progress of emerging antisense oligonucleotide drugs and the targeting of un-druggable sites in oncology. The talk will explore methods in drug delivery and provide results of progress made in clinical trials.
5. **Collaborate with GSK and Learn about IMI COMPACT**
Steve Hood, Director of Bioimaging and former Director of GSK's Oligonucleotide Delivery Gold Team, discusses industry collaboration through the Innovative Medicines Initiative (IMI) Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT). With a focus on biological barriers, Dr Hood will address questions such as: What are the challenges of Oligo Delivery? How do we optimise delivery? Who are COMPACT and what have they achieved?
6. **Overcome challenges in the delivery of small and large nucleic acids to cancers with AstraZeneca**
Sanyogitta Puri, Associate Principle Scientist, explores the formulation of siRNA versus plasmids in an address that will discuss the challenges of delivering small and large scale nucleic acids to cancers.

[View more information](#)

GET INVOLVED:

Secure your place by **30th November** to take advantage of the **£200 earlybird**. Register online at www.therapeutics-rna.com

Sponsorship enquires: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

Delegate enquires: Contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk

WHO WILL YOU MEET?

Now in its 8th year, our growing community of RNA experts who have previously attended include:

Advanced Cell Diagnostics SRL, Affymetrix, Aldevron, Alexion GmbH, Alios Biopharma, Amgen GmbH, Aptamer Group, AstraZeneca, Avencia Group, Bayer Pharma AG, BioNTech AG, Biopharm Insight, BioPharmaLogic Ltd, Boehringer Ingelheim, Boulton Wade Tennant, Covington & Burling LLP, CRISPR Therapeutics, Cristal Therapeutics, CureVac GmbH, Drug Target Review, Eberhard-Karls-University Tuebingen, Erdmann Technologies GmbH, Galderma France, GlaxoSmithKline, GlobalAcorn Ltd, Gustave Roussy, Institut Scientifique De Sante Publique Louis, Institute for Research in Biomedicine (IRB Barcelona), InteRNA Technologies, Isarna Therapeutics GmbH, Janssen Pharmaceutica NV, K.U.Leuven, Karolinska Institutet, Leeds University, Leiden University Medical Center, Lipocalyx, MHRA, MiNA Therapeutics, Noxxon Pharma AG, ProQR Therapeutics, RCSI Royal College of Surgeons in Ireland,, ReNeuron Group Plc, Rigontec GmbH, RNA Therapeutics, Royal College Of Surgeons In Ireland, Santaris Pharma A/S, Sarepta Therapeutics, Sheffield Hallam University, Silenseed, Skoltech, Sofinnova Partners, Sylentis, Technology Networks, The University of Southampton, Theraldia Consulting, ThermoFisher, Translational Oncology (TRON), Tromso University, UCL, Universita Magna Graecia - Catanzaro, Universite Paris Sud, University College Cork, University of Amsterdam, University of Southern Denmark, University Of Twente / 20Med, University Paris Sud, Vascular and Genomic Center Changhua Christian Hospital

Register online at: www.therapeutics-rna.com

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>